TYRA-300 for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Sep 2022: Trial registered, NCT05544552
  2. 22 Nov 2022: Trial started, NCT05544552

The trials

NCT05544552: Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

State
Under way
Phase
Phase 1 and Phase 2
People
310 planned
Started
22 Nov 2022
Primary completion
Nov 2026
Arms
Phase 1 Part A - dose escalation, Phase 1 Part B - dose expansion, Phase 2
Results
None posted
  1. 16 Sep 2022: Trial registered
  2. 22 Nov 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.